GBR-1342

N/A

Report date: 2026/03/19 17:18:39

Base Information

Drug NameGBR-1342

Drug Alias NameGBR-1342ISB-1342

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsCytotoxic T lymphocytes modulatorsAnti-CD3 +[4]

TargetsLymphocyte differentiation antigen CD38T cell surface glycoprotein CD3

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesGlenmark Pharmaceuticals Ltd

China Registration ClassN/A

Develop Information

Active CompaniesGlenmark Pharmaceuticals Ltd

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A